Literature DB >> 18212229

PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator.

Terence Z Wong1, Jeffrey L Lacy, Neil A Petry, Thomas C Hawk, Thomas A Sporn, Mark W Dewhirst, Gordana Vlahovic.   

Abstract

OBJECTIVE: Copper-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) and copper-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM) are being studied as potential markers of hypoxia and perfusion, respectively. The use of short-lived radionuclides (e.g., 62Cu) has advantages for clinical PET, including a lower radiation dose than long-lived radionuclides and serial imaging capability. A 62Zn/62Cu microgenerator and rapid synthesis kits now provide a practical means of producing 62Cu-PTSM and 62Cu-ATSM on-site. Tumors can be characterized with 62Cu-PTSM, 62Cu-ATSM, and 18F-FDG PET scans during one session. We present the initial clinical data in two patients with lung neoplasms.
CONCLUSION: Hypoxia and perfusion are important parameters in tumor physiology and can have major implications in diagnosis, prognosis, treatment planning, and response to therapy. We have shown the feasibility of performing 62Cu-ATSM and 62Cu-PTSM PET together with FDG PET/CT during a single imaging session to provide information on both perfusion and hypoxia and tumor anatomy and metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18212229      PMCID: PMC2980329          DOI: 10.2214/AJR.07.2876

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  18 in total

1.  Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy.

Authors:  J Lewis; R Laforest; T Buettner; S Song; Y Fujibayashi; J Connett; M Welch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.

Authors:  K S Chao; W R Bosch; S Mutic; J S Lewis; F Dehdashti; M A Mintun; J F Dempsey; C A Perez; J A Purdy; M J Welch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

3.  Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM.

Authors:  N G Haynes; J L Lacy; N Nayak; C S Martin; D Dai; C J Mathias; M A Green
Journal:  J Nucl Med       Date:  2000-02       Impact factor: 10.057

4.  The zinc-62/copper-62 generator: a convenient source of copper-62 for radiopharmaceuticals.

Authors:  G D Robinson; F W Zielinski; A W Lee
Journal:  Int J Appl Radiat Isot       Date:  1980-02

5.  Copper-62-pyruvaldehyde bis(N-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans.

Authors:  T R Wallhaus; J Lacy; R Stewart; J Bianco; M A Green; N Nayak; C K Stone
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

6.  The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography.

Authors:  Ken-Ichiro Matsumoto; Lawrence Szajek; Murali C Krishna; John A Cook; Jurgen Seidel; Kelly Grimes; Joann Carson; Anastasia L Sowers; Sean English; Michael V Green; Stephen L Bacharach; William C Eckelman; James B Mitchell
Journal:  Int J Oncol       Date:  2007-04       Impact factor: 5.650

7.  Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.

Authors:  J S Lewis; T L Sharp; R Laforest; Y Fujibayashi; M J Welch
Journal:  J Nucl Med       Date:  2001-04       Impact factor: 10.057

8.  Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.

Authors:  Rebecca L Aft; Jason S Lewis; Fanjie Zhang; Joonyoung Kim; Michael J Welch
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Authors:  Farrokh Dehdashti; Mark A Mintun; Jason S Lewis; Jeffrey Bradley; Ramaswamy Govindan; Richard Laforest; Michael J Welch; Barry A Siegel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

10.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Authors:  Farrokh Dehdashti; Perry W Grigsby; Mark A Mintun; Jason S Lewis; Barry A Siegel; Michael J Welch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

View more
  20 in total

1.  Towards new horizons in brain PET.

Authors:  Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06       Impact factor: 9.236

2.  Thermal dose fractionation affects tumour physiological response.

Authors:  Donald E Thrall; Paolo Maccarini; Paul Stauffer; James Macfall; Marlene Hauck; Stacey Snyder; Beth Case; Keith Linder; Lan Lan; Linda McCall; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

3.  Copper-64 Radiopharmaceuticals for Oncologic Imaging.

Authors:  Jason P Holland; Riccardo Ferdani; Carolyn J Anderson; Jason S Lewis
Journal:  PET Clin       Date:  2009-01

4.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

5.  Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.

Authors:  K Tateishi; U Tateishi; M Sato; S Yamanaka; H Kanno; H Murata; T Inoue; N Kawahara
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-14       Impact factor: 3.825

Review 6.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.

Authors:  Richard L Wahl; Joseph M Herman; Eric Ford
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 7.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 8.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Authors:  J P Holland; J S Lewis; F Dehdashti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

Review 9.  Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.

Authors:  Yaacov Richard Lawrence; Maria Werner-Wasik; Adam P Dicker
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

10.  Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).

Authors:  Ernst J Postema; Alexander J B McEwan; Terence A Riauka; Piyush Kumar; Dacia A Richmond; Douglas N Abrams; Leonard I Wiebe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-09       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.